DE60328517D1 - Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung - Google Patents

Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung

Info

Publication number
DE60328517D1
DE60328517D1 DE60328517T DE60328517T DE60328517D1 DE 60328517 D1 DE60328517 D1 DE 60328517D1 DE 60328517 T DE60328517 T DE 60328517T DE 60328517 T DE60328517 T DE 60328517T DE 60328517 D1 DE60328517 D1 DE 60328517D1
Authority
DE
Germany
Prior art keywords
lycopine
treatment
diseases associated
new use
androgen effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328517T
Other languages
English (en)
Inventor
Luca Barella
Regina Goralczyk
Ulrich Siler
Karin Wertz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Application granted granted Critical
Publication of DE60328517D1 publication Critical patent/DE60328517D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60328517T 2002-12-06 2003-12-04 Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung Expired - Lifetime DE60328517D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02027244 2002-12-06
PCT/EP2003/013665 WO2004052351A1 (en) 2002-12-06 2003-12-04 Novel use of lycopene

Publications (1)

Publication Number Publication Date
DE60328517D1 true DE60328517D1 (de) 2009-09-03

Family

ID=32479709

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328517T Expired - Lifetime DE60328517D1 (de) 2002-12-06 2003-12-04 Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung

Country Status (9)

Country Link
US (1) US20060069151A1 (de)
EP (1) EP1569628B1 (de)
JP (1) JP2006510647A (de)
CN (1) CN1720030A (de)
AU (1) AU2003294778A1 (de)
DE (1) DE60328517D1 (de)
ES (1) ES2329238T3 (de)
IL (1) IL168386A (de)
WO (1) WO2004052351A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146496A0 (en) 2001-11-14 2002-07-25 Lycored Natural Prod Ind Ltd Carotenoid composition and method for protecting skin
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
ES2245609B1 (es) * 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
FR2877572B1 (fr) * 2004-11-10 2008-03-21 Claude Bonne Nouvelles compositions pharmaceutiques, alimentaires ou cosmetiques pour prevenir et traiter l'acne
WO2007056941A1 (fr) * 2005-11-15 2007-05-24 Jingcai Cheng Utilisation de composes a base d'isothiocyanates dans le traitement de maladies prostatiques et du cancer de la peau
US20070135521A1 (en) * 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
TW200738227A (en) 2006-04-03 2007-10-16 Panatoz Corp One kind of multi-carotenoids and its administration
EA200802072A1 (ru) * 2006-04-13 2009-04-28 Камедика Лимитед Ликопин для лечения нарушения обмена веществ
WO2007131767A2 (en) * 2006-05-15 2007-11-22 Dsm Ip Assets B.V. Novel actives against prostate carcinoma
US7805004B2 (en) * 2007-02-28 2010-09-28 Microsoft Corporation Radical set determination for HMM based east asian character recognition
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
JP2010105984A (ja) * 2008-10-31 2010-05-13 Unitika Ltd 経口投与組成物
WO2011039175A1 (en) * 2009-09-29 2011-04-07 Bodo Melnik Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus
CN102132767B (zh) * 2011-03-09 2013-05-08 北京桑普生物化学技术有限公司 含有姜黄素或姜黄素衍生物的复合饲料添加剂及用途
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
CN103054025A (zh) * 2013-01-04 2013-04-24 浙江大学 防治前列腺疾病的保健食品组合物
PL2976070T3 (pl) * 2013-03-19 2021-12-27 Lycored Ltd. Przeciwzapalne synergistyczne kombinacje astaksantyny z likopenem i kwasem karnozowym
US9592264B2 (en) 2013-04-05 2017-03-14 U.S. Nutraceuticals, LLC Delivery system for saw palmetto extract and carotenoid
EP2929879B1 (de) * 2014-04-07 2020-03-18 Gonadosan GmbH Kombinationspräparat gegen infertilität, die mit endometriose assoziiert ist
US20180271118A1 (en) 2015-01-15 2018-09-27 Dsm Ip Assets B.V. Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health
KR20170103823A (ko) * 2015-01-15 2017-09-13 디에스엠 아이피 어셋츠 비.브이. 인간 기능 식품용의 25-하이드록시 비타민 d 및 항산화제/항염증제의 조합물
WO2016199147A1 (en) * 2015-06-11 2016-12-15 Nina Elya Ltd. A composition for treatment of hair loss and regrowth stimulation
AT518311A1 (de) * 2016-03-07 2017-09-15 Gonadosan Gmbh Kombinationspräparat
IT201600081379A1 (it) * 2016-08-03 2018-02-03 Neilos S R L Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
CN107348304B (zh) * 2017-07-21 2024-02-09 博凯药业有限公司 含有茶多酚和姜黄素的泡腾片及其制备方法
IT202000003964A1 (it) * 2020-02-26 2021-08-26 Umberto Cornelli Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale
EP4000626A1 (de) * 2020-11-16 2022-05-25 concrete flowers GmbH Pharmazeutisches präparat
CN112715938A (zh) * 2020-12-28 2021-04-30 完美（中国）有限公司 一种抑制前列腺增生的组合物
US20220347120A1 (en) * 2021-04-30 2022-11-03 Muhammed Majeed Compositions for management of polycystic ovary syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2740042B1 (fr) * 1995-10-23 1997-11-14 Oreal Support, et composition contenant ce support et un actif cosmetique ou dermatologique stabilise
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US6399115B2 (en) * 1999-09-10 2002-06-04 Glenn Braswell Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
GB9922751D0 (en) * 1999-09-27 1999-11-24 Kenton Corp Limited A pharmaceutical composition for stabilising atherosclerotic plaques
FR2799370B1 (fr) * 1999-10-07 2005-08-19 Oreal Utilisation du lycopene dans des compositions destinees a traiter les signes cutanes du vieillissement
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
DE10109798A1 (de) * 2001-03-01 2002-09-12 Aventis Pharma Gmbh Gesundheitsfördernde Zusammensetzung von Verbindungen
IL141038A (en) * 2001-01-23 2006-10-05 Lycored Natural Prod Ind Ltd Use of carotenoids for the preparation of substances for the treatment of high blood pressure
EP1314438A1 (de) * 2001-11-23 2003-05-28 Nutricia N.V. Antiproliferative Zusammensetzung

Also Published As

Publication number Publication date
IL168386A (en) 2010-12-30
WO2004052351A1 (en) 2004-06-24
CN1720030A (zh) 2006-01-11
AU2003294778A1 (en) 2004-06-30
EP1569628A1 (de) 2005-09-07
US20060069151A1 (en) 2006-03-30
JP2006510647A (ja) 2006-03-30
ES2329238T3 (es) 2009-11-24
EP1569628B1 (de) 2009-07-22

Similar Documents

Publication Publication Date Title
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE602005020293D1 (de) Zur behandlung von hyperproliferationserkrankungen und mit angiogenese assoziierten krankheiten geeignete pyrrolotriazinderivate
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition